2023
DOI: 10.1016/s0140-6736(23)00002-8
|View full text |Cite
|
Sign up to set email alerts
|

Clinical aspects of snakebite envenoming and its treatment in low-resource settings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
22
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(22 citation statements)
references
References 170 publications
0
22
0
Order By: Relevance
“…The reviews have been published in peer-reviewed journals with an average impact factor of 3.56, with one journal without an impact factor. After publication the HP review papers were cited 3.73 times per year on average, ranging from highly specialized journals, like the Journal of Apicultural Research [ 30 ] to general high impact journals, like the Lancet [ 31 ].…”
Section: Resultsmentioning
confidence: 99%
“…The reviews have been published in peer-reviewed journals with an average impact factor of 3.56, with one journal without an impact factor. After publication the HP review papers were cited 3.73 times per year on average, ranging from highly specialized journals, like the Journal of Apicultural Research [ 30 ] to general high impact journals, like the Lancet [ 31 ].…”
Section: Resultsmentioning
confidence: 99%
“…Patient care outcomes may be directly influenced by the delay between envenomation and antivenom administration for susceptible snakebite envenomation cases. As most snakebites are concentrated in rural areas of low-resource settings, investigations may be limited to basic tests, such as full blood counts, 20-minute whole blood clotting test, urine examinations, and serum renal function tests [ 24 ]. The increased platelet hyperactivity may result in thrombocytopenia, as demonstrated in B arietans envenomation [ 9 ].…”
Section: Discussionmentioning
confidence: 99%
“…Snakebite envenoming represents a persistent and significant global health challenge, with an annual global incidence estimated to be between 1.8 - 2.7 million envenomings, leading to approximately 81,000 - 138,000 fatalities and many more indefinable debilitating consequences [ 1 - 3 ]. Despite the longstanding history of human exposure to snakebite envenomings [ 2 ], antivenoms consisting of plasma-derived antibodies (or fragments thereof) from hyperimmunized animals have been the primary treatment option since they were first developed by Albert Calmette, Césaire Phisalix, and Gabriel Bertrand in the late 19 th century [ 4 , 5 ].…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, the relatively high cost of goods that antivenoms have may impose a significant economic burden on snakebite victims and/or healthcare systems in low-income areas with a high incidence of snakebite envenoming [ 13 ]. This latter aspect, in particular, is critical for the deployment of antivenoms, as most snakebite victims worldwide are found amongst poor, rural populations [ 3 , 14 ].…”
Section: Introductionmentioning
confidence: 99%